CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
We have now added a new section called the "Assay History List" to the "At A Gla...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...